CORRECTION FROM SOURCE: Vaso Corporation Announces Financial Results ...
CORRECTION FROM SOURCE: Vaso Corporation Announces Financial Results ...
Source: pr-inside.com
Page 8 - Jun Ma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jun Ma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jun Ma Today - Breaking & Trending Today
Low Income Linked to High Recurrence Risk, Poorer Survival in Women With ER-Positive Breast Cancer
BUFFALO, N.Y. (PRWEB) February 21, 2023 -- · Few prior studies have evaluated how socioeconomic status affects tumor biology· Observational study included
Source: prweb.com
Income level impacts tumor recurrence and survival in women with ER-positive breast cancer
Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more-aggressive tumors and significantly lower overall survival (OS) than those in higher-income neighborhoods, according to research led by Roswell Park Comprehensive Cancer Center.
Source: news-medical.net
Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting
Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting
Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting
Source: investegate.co.uk